{"id":932,"date":"2025-02-16T22:59:18","date_gmt":"2025-02-16T22:59:18","guid":{"rendered":"http:\/\/elmoustkbal.com\/?p=932"},"modified":"2025-02-16T22:59:18","modified_gmt":"2025-02-16T22:59:18","slug":"montebon-chua-m","status":"publish","type":"post","link":"https:\/\/elmoustkbal.com\/?p=932","title":{"rendered":"\ufeffMontebon Chua, M"},"content":{"rendered":"<p>\ufeffMontebon Chua, M.S. recorded up to Day 4, safety outcomes up to Month 6, and serious adverse events related to vaccination up to Year 3. Results Pre-specified criteria for non-inferiority of MenACWY-TT versus Men-PS were met in terms of rSBA vaccine response and incidence of grade 3 general symptoms. At Month 1, 82.7%C96.3% of MenACWY-TT and 69.7%C91.7% in Men-PS recipients had a vaccine response for each serogroup. At Year 3, 99.1% and 92.9% of MenACWY-TT recipients retained rSBA titres 8 and 128, respectively, as compared PU 02 to 86.7% and 80.0% in the Men-PS group. Both vaccines had a clinically acceptable safety profile, although injection site redness and swelling were more frequent in MenACWY-TT recipients. Conclusions These results suggest that MenACWY-TT could protect adolescents and adults against meningococcal disease up <a href=\"http:\/\/daphne.palomar.edu\/design\/space2.html\"> FLJ12455<\/a> to three years post-vaccination. Trial registration This study is usually registered at http:\/\/www.clinicaltrials.gov\/NCT00356369. Keywords: Quadrivalent meningococcal vaccine, Conjugate vaccine, Bactericidal activity, Persistence, Safety, The Philippines, Saudi Arabia Background is a major cause of endemic and epidemic invasive bacterial disease worldwide and is associated with high morbidity [1-3]. Most invasive meningococcal disease is usually caused by six of the 12 known serogroups, namely serogroups A, B, C, W-135, Y, and more recently X [2,3]. The epidemiology of meningococcal disease varies geographically and over time, and the increasing trend of international travel and migration facilitates the rapid intercontinental spread of meningococcal isolates [4-7]. Moreover, new strains may also appear in a region by bacterial capsular switching [3,8]. In Asia and the Middle East, serogroups A, C, and W-135 are the most common serogroups [3,5,9]. In the Philippines, an outbreak caused by serogroup A occurred in 2004C2005 [3,10]. A previous outbreak had been reported in 1989, but data on serogroup distribution from this earlier outbreak are not available [11]. In Saudi Arabia, has been responsible for various outbreaks during the annual Hajj pilgrimage [12,13]. An outbreak caused by serogroup A occurred in 1987 and an outbreak caused by serogroup W-135 was also reported in 2000C2001 [12-15]. Pilgrims to the Hajj are at increased risk for contamination because of overcrowding, shared living facilities, and close contact with people from various parts of the world, which are all known risk factors for meningococcal disease [13]. Immunisation with vaccines against multiple serogroups is likely to be the best strategy to protect individuals against meningococcal diseases. In both the Philippines and Saudi Arabia, vaccination is recommended for individuals who are at increased risk for meningococcal contamination. In particular, vaccination is used to protect Hajj pilgrims against invasive meningococcal disease in Saudi Arabia [5,12]. In response to the 1987 outbreak, vaccination with a bivalent polysaccharide vaccine against serogroups A and <a href=\"https:\/\/www.adooq.com\/pu-02.html\">PU 02<\/a> C was recommended for Hajj pilgrims, and the vaccination policy was updated following the outbreak in 2000C2001 to include serogroup W-135 [7]. Presently, Saudi Arabia requires proof of vaccination with a quadrivalent meningococcal serogroup A, C, W-135, and Y vaccine to issue Hajj pilgrimage visa for all those arrivals. Moreover, administration of chemoprophylaxis at the port of entry to all arrivals from the countries of the African meningitis belt is required in order to lower the carriage rate among Hajj pilgrims [15,16]. Plain meningococcal polysaccharide vaccines against serogroups A, C, W-135, and Y are available for use PU 02 in adults and children over two years of age. However, these vaccines are poorly immunogenic for serogroups C, W-135 and Y, do not elicit long-term protection in younger children, do not.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffMontebon Chua, M.S. recorded up to Day 4, safety outcomes up to Month 6, and serious adverse events related to vaccination up to Year 3.&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29],"tags":[],"class_list":["post-932","post","type-post","status-publish","format-standard","hentry","category-prostanoid-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffMontebon Chua, M - DHFR inhibitors in non-small cell lung cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/elmoustkbal.com\/?p=932\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffMontebon Chua, M - DHFR inhibitors in non-small cell lung cancer\" \/>\n<meta property=\"og:description\" content=\"\ufeffMontebon Chua, M.S. recorded up to Day 4, safety outcomes up to Month 6, and serious adverse events related to vaccination up to Year 3.&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/elmoustkbal.com\/?p=932\" \/>\n<meta property=\"og:site_name\" content=\"DHFR inhibitors in non-small cell lung cancer\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-16T22:59:18+00:00\" \/>\n<meta name=\"author\" content=\"webmaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"webmaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932\"},\"author\":{\"name\":\"webmaster\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#\\\/schema\\\/person\\\/6ba91697c07f5b1e48a1c50fec2fd4a0\"},\"headline\":\"\ufeffMontebon Chua, M\",\"datePublished\":\"2025-02-16T22:59:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932\"},\"wordCount\":554,\"articleSection\":[\"Prostanoid Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932\",\"url\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932\",\"name\":\"\ufeffMontebon Chua, M - DHFR inhibitors in non-small cell lung cancer\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#website\"},\"datePublished\":\"2025-02-16T22:59:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#\\\/schema\\\/person\\\/6ba91697c07f5b1e48a1c50fec2fd4a0\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/elmoustkbal.com\\\/?p=932\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/?p=932#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/elmoustkbal.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffMontebon Chua, M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#website\",\"url\":\"https:\\\/\\\/elmoustkbal.com\\\/\",\"name\":\"DHFR inhibitors in non-small cell lung cancer\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/elmoustkbal.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/elmoustkbal.com\\\/#\\\/schema\\\/person\\\/6ba91697c07f5b1e48a1c50fec2fd4a0\",\"name\":\"webmaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g\",\"caption\":\"webmaster\"},\"sameAs\":[\"http:\\\/\\\/elmoustkbal.com\"],\"url\":\"https:\\\/\\\/elmoustkbal.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffMontebon Chua, M - DHFR inhibitors in non-small cell lung cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/elmoustkbal.com\/?p=932","og_locale":"en_US","og_type":"article","og_title":"\ufeffMontebon Chua, M - DHFR inhibitors in non-small cell lung cancer","og_description":"\ufeffMontebon Chua, M.S. recorded up to Day 4, safety outcomes up to Month 6, and serious adverse events related to vaccination up to Year 3.&hellip;","og_url":"https:\/\/elmoustkbal.com\/?p=932","og_site_name":"DHFR inhibitors in non-small cell lung cancer","article_published_time":"2025-02-16T22:59:18+00:00","author":"webmaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"webmaster","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/elmoustkbal.com\/?p=932#article","isPartOf":{"@id":"https:\/\/elmoustkbal.com\/?p=932"},"author":{"name":"webmaster","@id":"https:\/\/elmoustkbal.com\/#\/schema\/person\/6ba91697c07f5b1e48a1c50fec2fd4a0"},"headline":"\ufeffMontebon Chua, M","datePublished":"2025-02-16T22:59:18+00:00","mainEntityOfPage":{"@id":"https:\/\/elmoustkbal.com\/?p=932"},"wordCount":554,"articleSection":["Prostanoid Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/elmoustkbal.com\/?p=932","url":"https:\/\/elmoustkbal.com\/?p=932","name":"\ufeffMontebon Chua, M - DHFR inhibitors in non-small cell lung cancer","isPartOf":{"@id":"https:\/\/elmoustkbal.com\/#website"},"datePublished":"2025-02-16T22:59:18+00:00","author":{"@id":"https:\/\/elmoustkbal.com\/#\/schema\/person\/6ba91697c07f5b1e48a1c50fec2fd4a0"},"breadcrumb":{"@id":"https:\/\/elmoustkbal.com\/?p=932#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/elmoustkbal.com\/?p=932"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/elmoustkbal.com\/?p=932#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/elmoustkbal.com\/"},{"@type":"ListItem","position":2,"name":"\ufeffMontebon Chua, M"}]},{"@type":"WebSite","@id":"https:\/\/elmoustkbal.com\/#website","url":"https:\/\/elmoustkbal.com\/","name":"DHFR inhibitors in non-small cell lung cancer","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/elmoustkbal.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/elmoustkbal.com\/#\/schema\/person\/6ba91697c07f5b1e48a1c50fec2fd4a0","name":"webmaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/66fbd3a9ef48c403fd533a73978e5557cc8b799f7e461809e4f768dafe87f404?s=96&d=mm&r=g","caption":"webmaster"},"sameAs":["http:\/\/elmoustkbal.com"],"url":"https:\/\/elmoustkbal.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts\/932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=932"}],"version-history":[{"count":1,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts\/932\/revisions"}],"predecessor-version":[{"id":933,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=\/wp\/v2\/posts\/932\/revisions\/933"}],"wp:attachment":[{"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/elmoustkbal.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}